Cholamandalam Investment & Finance Company Ltd (CHOLAFIN) Q1 FY27 Results Analysis: PAT Jumps 45.6%, Stage 3 Rises 24 bps

CompoundingAI Research Updated July 28, 2026 2 min read
Positive

Cholamandalam Investment & Finance Company Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 8,833.38 Cr (+21.90% YoY) and PAT growth of +45.57% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 28, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 8,833.38 Cr (+21.90% YoY)
PAT (Q1)Rs. 1,653.59 Cr (+45.57% YoY)
EPS (Q1)Rs. 19.40 (+43.67% YoY)
Market capRs. 153,631.92 Cr
CMPRs. 1,801.80

Quarter Snapshot

CHOLAFIN delivered strong Q1 results with 21.9% revenue growth and 45.6% PAT growth, driven by operating leverage and margin expansion. AUM grew 22.5% YoY, within guidance, while credit costs remained contained. However, asset quality saw a modest deterioration with Stage 3 rising 24 bps QoQ, warranting monitoring.

Key Investment Insights

Key Positives

  • Revenue grew 21.9% YoY to Rs.8,932.95 Cr, PAT grew 45.6% YoY to Rs.1,653.59 Cr.
  • PPOP grew 29.3% YoY, with cost-to-income improving 118 bps to 43.28%.
  • AUM grew 22.5% YoY to Rs.2,54,392 Cr, within the guided range of 20-23%.
  • Credit costs contained: impairment grew only 4.5% YoY despite 22% AUM growth.
  • Others segment PBT surged 115% YoY, showing new business scale-up.
  • Capital adequacy ratio improved to 19.81% from 19.21% QoQ, well above regulatory minimum.
  • Net worth grew 29.9% YoY to Rs.32,078 Cr, driven by retained earnings and CCD conversion.

Risk Factors

  • Gross Stage 3 increased to 3.29% from 3.05% QoQ, GNPA increased to 4.50% from 4.36% QoQ.
  • Provision coverage ratio (Stage 3) declined to 45.73% from 47.29% QoQ.
  • LAP and Home Loans asset growth (17% and 23% YoY) lagged the 25-30% FY27 guidance, though one quarter is insufficient to judge full-year trajectory.
Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by CompoundingAI — AI research platform for Indian stocks, every claim cited from primary filings

Login Now